North America Veterinary Medicine Market
Market Report I 2025-04-01 I 350 Pages I Data Bridge Market Research
North America veterinary medicine market is expected to reach USD 31.73 billion by 2032 from USD 19.17 billion in 2024, growing at a CAGR of 6.5% in the forecast period of 2025 to 2032.
Market Segmentation:
North America Veterinary Medicine Market, By Type (Therapeutics and Diagnostics), Application (Bacterial Diseases, Canine Atopic Dermatitis, Heminthes Infection, Animal Cancer, Foot and Mouth Disease, Autoimmune Diseases, Bluetongue, and Others), Animal Type (Companion Animals and Production Animal), End User (Veterinary Hospitals, Veterinary Clinics, Animal And Veterinary Farms, Reference Laboratories, Academic And Research Institute, Point-Of-Care Testing/In-House Testing, and Others), Distribution Channel (Retail Sales, Direct Tender, and Others), Country (U.S., Canada, and Mexico) - Industry Trends & Forecast To 2032
Overview of the North America Veterinary Medicine Market are:
Driver
- Increasing Pet Ownership Boosts Demand For Veterinary Services
Restraint
- High Veterinary Care Costs Limit Market Accessibility
Opportunity
- Increasing Number of Animals Leading to The Demand of Veterinary Medicine
Market Players:
Some of the major players operating in the North America veterinary medicine market are:
- Zoetis Services LLC
- Merck & Co., Inc.
- Elanco or its affiliates
- C.H. Boehringer Ingelheim International GmbH
- IDEXX LABORATORIES, INC
- AB Science
- AdvaCare Pharma
- ALMAX IMAGING srl
- Anivive
- BIOMERIEUX
- Bionote USA Inc.
- Bio-Rad Laboratories, Inc.
- CANON MEDICAL SYSTEMS EUROPE B.V.
- Cargill, Incorporated
- Ceva
- CureLab Oncology
- Dechra Pharmaceuticals Limited
- Narang Medical Limited
- Neogen Corporation
- NIPPON ZENYAKU KOGYO CO., LTD.
- Demeditec Diagnostics GmbH
- DHN International
- Diagnostic Imaging Systems
- ESAOTE SPA
- Eurofins Scientific
- Evonik Industries AG
- FUJIFILM Holdings Corporation
- Gold Standard Diagnostics
- Hallmarq Veterinary Imaging
- Hebei Veyong Pharmaceutical Co., Ltd.
- IBIS S.R.L.
- Virbac
- VMRD, Inc.
- Heska Corporation
- Karyopharm
- Meridian Bioscience, Inc.
- VetDC
- Novavive Inc.
- Nutreco
- PLANMECA O?
- Randox Laboratories Ltd.
- Torigen Pharmaceuticals Inc.
- Thermo Fisher Scientific Inc.
- Vetoquinol
TABLE OF CONTENTS
1 INTRODUCTION 169
1.1 OBJECTIVES OF THE STUDY 169
1.2 MARKET DEFINITION 169
1.3 OVERVIEW OF THE NORTH AMERICA VETERINARY MEDICINE MARKET 169
1.4 CURRENCY AND PRICING 172
1.5 LIMITATIONS 172
1.6 MARKETS COVERED 172
2 MARKET SEGMENTATION 180
2.1 MARKETS COVERED 180
2.2 GEOGRAPHICAL SCOPE 181
2.3 YEARS CONSIDERED FOR THE STUDY 182
2.4 DBMR TRIPOD DATA VALIDATION MODEL 183
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 186
2.6 MULTIVARIATE MODELLING 187
2.7 DBMR MARKET POSITION GRID 188
2.8 MARKET END USER COVERAGE GRID 189
2.9 VENDOR SHARE ANALYSIS 190
2.10 SECONDARY SOURCES 191
2.11 ASSUMPTIONS 191
3 EXECUTIVE SUMMARY 192
4 PREMIUM INSIGHTS 201
4.1 PESTAL ANALYSIS 203
4.2 PORTERS FIVE FORCES ANALYSIS 204
4.3 PIPELINE ANALYSIS 205
4.4 TOP ENTITIES BASED ON R&D GLANCE FOR VETERINARY MEDICINE MARKET 206
4.5 EPIDEMIOLOGY 207
5 NORTH AMERICA VETERINARY MEDICINE MARKET: REGULATIONS 208
6 MARKET OVERVIEW 210
6.1 DRIVERS 212
6.1.1 INCREASING PET OWNERSHIP BOOSTS DEMAND FOR VETERINARY SERVICES 212
6.1.2 RISING ANIMAL DISEASES DRIVE NEED FOR ADVANCED VETERINARY CARE 213
6.1.3 VETERINARY MEDICINE ADVANCES IMPROVE DIAGNOSIS AND TREATMENT OPTIONS 213
6.1.4 RISING DEMAND FOR ANIMAL-DERIVED FOOD PRODUCTS INCREASES VETERINARY NEEDS 214
6.2 RESTRAINTS 216
6.2.1 HIGH VETERINARY CARE COSTS LIMIT MARKET ACCESSIBILITY 216
6.2.2 LACK OF AWARENESS ABOUT ANIMAL HEALTH LIMITS PROPER VETERINARY CARE ACCESS 216
6.3 OPPORTUNITIES 218
6.3.1 INCREASING NUMBER OF ANIMALS LEADING TO THE DEMAND OF VETERINARY MEDICINE 218
6.3.2 GROWTH IN ANIMAL HEALTH BIOTECHNOLOGY 218
6.3.3 GROWTH IN DEMAND FOR NUTRITIONAL SUPPLEMENTS 219
6.4 CHALLENGES 220
6.4.1 CHALLENGES OF REGULATORY COMPLIANCE AND COMPLEXITY 220
6.4.2 SHORTAGE OF VETERINARY PROFESSIONALS 220
7 NORTH AMERICA VETERINARY MEDICINE MARKET, BY TYPE 222
7.1 OVERVIEW 223
7.2 THERAPEUTICS 226
7.2.1 PHARMACEUTICALS 228
7.2.1.1 ANTIBIOTICS 229
7.2.1.1.1 TETRACYCLINE 229
7.2.1.1.2 PENICILLINS 229
7.2.1.1.3 MACROLIDES 229
7.2.1.1.4 AMINOGLYCOSIDES 229
7.2.1.1.5 LINCOSAMIDES 229
7.2.1.1.6 COLISTIN 229
7.2.1.1.7 OTHERS 229
7.2.1.2 PARASITICIDES 230
7.2.1.2.1 BENZIMIDAZOLES 230
7.2.1.2.2 MACROCYCLIC LACTONES 230
7.2.1.2.3 PYRETHROIDS 230
7.2.1.2.4 AMPROLIUM 230
7.2.1.2.5 NITROIMIDAZOLES 230
7.2.1.2.6 PIPERAZINE 230
7.2.1.2.7 OTHERS 230
7.2.1.3 ANALGESICS/ANTI-INFLAMMATORY (NSAIDS) 231
7.2.1.3.1 CARPROFEN 231
7.2.1.3.2 MELOXICAM 231
7.2.1.3.3 PHENYLBUTAZONE 231
7.2.1.3.4 ACETAMINOPHEN 231
7.2.1.3.5 FIROCOXIB 231
7.2.1.3.6 DERACOXIB 231
7.2.1.3.7 OTHERS 231
7.2.1.4 ANTIHISTAMINES 232
7.2.1.4.1 CETIRIZINE 232
7.2.1.4.2 BROMPHENIRAMINE 232
7.2.1.4.3 DIPHENHYDRAMINE 232
7.2.1.4.4 TERFENADINE 232
7.2.1.4.5 TRIMEPRAZINE 232
7.2.1.4.6 OTHERS 232
7.2.1.5 CORTICOSTEROIDS 233
7.2.1.5.1 DEXAMETHASONE 233
7.2.1.5.2 PREDNISOLONE 233
7.2.1.5.3 PREDNISONE 233
7.2.1.5.4 OTHERS 233
7.2.1.6 ANTIBLOAT 234
7.2.1.6.1 DOCUSATE 234
7.2.1.6.2 SIMETHICONE 234
7.2.1.6.3 OTHERS 234
7.2.1.7 HORMONAL 235
7.2.1.7.1 EQUINE CHORIONIC GONADOTROPIN 235
7.2.1.7.2 CLOPROSTENOL 235
7.2.1.7.3 OXYTOCIN 235
7.2.1.7.4 OTHERS 235
7.2.1.8 OPIOIDS 236
7.2.1.8.1 MU AGONISTS 236
7.2.1.8.1.1 METHADONE 237
7.2.1.8.1.2 MEPERIDINE 237
7.2.1.8.1.3 MORPHINE 237
7.2.1.8.1.4 OXYMORPHONE 237
7.2.1.8.1.5 OTHERS 237
7.2.1.8.2 PARTIAL MU AGONIST 238
7.2.1.8.2.1 BUPRENORPHINE 238
7.2.1.8.2.2 OTHERS 238
7.2.1.8.3 KAPPA AGONIST-MU ANTAGONIST 238
7.2.1.8.3.1 BUTORPHANOL 238
7.2.1.8.3.2 OTHERS 238
7.2.1.9 OTHERS 239
7.2.1.10 PHARMACEUTICALS BY DRUG TYPE 239
7.2.1.10.1 BRANDED 239
7.2.1.10.2 GENERIC 239
7.2.1.11 PHARMACEUTICALS BY PRESCRIPTION MODE 239
7.2.1.11.1 PRESCRIPTION BASED 239
7.2.1.11.2 OVER THE COUNTER 239
7.2.1.12 PHARMACEUTICALS BY ROUTE OF ADMINISTRATION, 240
7.2.1.12.1 ORAL 240
7.2.1.12.1.1 TABLETS 241
7.2.1.12.1.2 SOLUTIONS 241
7.2.1.12.1.3 POWDER 241
7.2.1.12.1.4 OTHERS 241
7.2.1.12.2 PARENTAL 241
7.2.1.12.2.1 INTRAVENOUS 241
7.2.1.12.2.2 SUBCUTANEOUS 241
7.2.1.12.2.3 OTHERS 241
7.2.1.12.3 TOPICAL 241
7.2.1.12.4 OTHERS 241
7.2.2 VACCINES 242
7.2.2.1 LIVE ATTENUATED VACCINES 242
7.2.2.2 TOXOID VACCINES 242
7.2.2.3 RECOMBINANT VACCINES 242
7.2.2.4 INACTIVATED VACCINES 242
7.2.2.5 OTHERS 242
7.2.3 BIOLOGICS 243
7.2.3.1 MARKETED 243
7.2.3.1.1 TOCERANIB 244
7.2.3.1.2 LOMUSTINE 244
7.2.3.1.3 CYCLOPHOSPHAMIDE 244
7.2.3.1.4 CHLORAMBUCIL 244
7.2.3.1.5 OTHERS 244
7.2.3.2 EMERGING 244
7.2.4 MEDICATED FEED ADDITIVES 245
7.2.4.1 ENZYMES 246
7.2.4.1.1 PHYTASE 247
7.2.4.1.2 CARBOHYDRASE 247
7.2.4.1.3 PROTEASE 247
7.2.4.1.4 AMYLASE 247
7.2.4.1.5 CELLULASE 247
7.2.4.1.6 MANNASE 247
7.2.4.1.7 GLUCANASE 247
7.2.4.1.8 XYLANASE 247
7.2.4.1.9 OTHERS 247
7.2.4.2 AMINO ACID 248
7.2.4.2.1 LYSINE 248
7.2.4.2.2 METHIONINE 248
7.2.4.2.3 THREONINE 248
7.2.4.2.4 TRYPTOPHAN 248
7.2.4.2.5 OTHERS 248
7.2.4.3 VITAMINS 249
7.2.4.3.1 FAT-SOLUBLE VITAMIN 249
7.2.4.3.1.1 VITAMIN A 250
7.2.4.3.1.2 VITAMIN E 250
7.2.4.3.1.3 VITAMIN D 250
7.2.4.3.1.4 VITAMIN K 250
7.2.4.3.2 WATER-SOLUBLE VITAMIN 250
7.2.4.3.2.1 VITAMIN B COMPLEX 250
7.2.4.3.2.2 VITAMIN C 250
7.2.4.4 ANTIOXIDANTS 251
7.2.4.4.1 BHA 251
7.2.4.4.2 BHT 251
7.2.4.4.3 ETHOXYQUIN 251
7.2.4.4.4 OTHERS 251
7.2.4.5 PROBIOTICS 252
7.2.4.6 LACTOBACILLI 252
7.2.4.7 BIFIDOBACTERIA 252
7.2.4.8 YEAST 252
7.2.4.9 STRETOCOCCUS THERMOPHILUS 252
7.2.4.10 FEED ACIDIFIERS 253
7.2.4.10.1 PROPIONIC ACID 253
7.2.4.10.2 FORMIC ACID 253
7.2.4.10.3 LACTIC ACID 253
7.2.4.10.4 CITRIC ACID 253
7.2.4.10.5 OTHERS 253
7.2.4.11 MYCOTOXIN DETOXIFIERS 254
7.2.4.11.1 MYCOTOXIN BINDERS 254
7.2.4.11.1.1 SILICATES 255
7.2.4.11.1.2 CLAYS 255
7.2.4.11.1.3 CHEMICAL POLYMERS 255
7.2.4.11.1.4 GLUCAN PRODUCTS 255
7.2.4.11.1.5 OTHERS 255
7.2.4.11.2 MYCOTOXIN MODIFIERS 255
7.2.4.12 PHYTOGENIC 256
7.2.4.12.1 ESSENTIAL OILS 256
7.2.4.12.2 HERBS & SPICES 256
7.2.4.12.3 OLEORESIN 256
7.2.4.12.4 OTHERS 256
7.2.4.13 CAROTENOIDS 257
7.2.4.13.1 BETA-CAROTENE 257
7.2.4.13.2 ASTAXANTHIN 257
7.2.4.13.3 LUTEIN 257
7.2.4.13.4 CANTHAXANTHIN 257
7.2.4.14 TRACE MINERALS 258
7.2.4.14.1 ZINC 258
7.2.4.14.2 COPPER 258
7.2.4.14.3 MANGANESE 258
7.2.4.14.4 IRON 258
7.2.4.14.5 SELENIUM 258
7.2.4.14.6 OTHERS 258
7.2.4.15 PRESERVATIVES 259
7.2.4.15.1 ANTICAKING AGENTS 259
7.2.4.15.2 MOLD INHIBITORS 259
7.2.4.16 FLAVOURS AND SWEETENERS 260
7.2.4.16.1 FLAVORS 260
7.2.4.16.2 SWEETENERS 260
7.2.4.16.2.1 SACCHARIN 261
7.2.4.16.2.2 NEOHESPERIDIN DIHYDROCHALCONE 261
7.2.4.16.2.3 GLYCYRRHIZIN 261
7.2.4.16.2.4 THAUMATIN 261
7.2.4.16.2.5 OTHERS 261
7.2.4.17 OTHERS 261
7.3 DIAGNOSTICS 262
7.3.1 INSTRUMENTS & DEVICES 263
7.3.1.1 IMAGING DEVICES 263
7.3.1.2 X-RAY IMAGING (RADIOGRAPHY) 264
7.3.1.2.1 SMALL ANIMALS 264
7.3.1.2.2 LARGE ANIMALS 264
7.3.1.3 ULTRASOUND 264
7.3.1.3.1 SMALL ANIMALS 264
7.3.1.3.2 LARGE ANIMALS 264
7.3.1.4 COMPUTED TOMOGRAPHY 265
7.3.1.4.1 SMALL ANIMALS 265
7.3.1.4.2 LARGE ANIMALS 265
7.3.1.5 MAGNETIC RESONANCE IMAGING 265
7.3.1.5.1 SMALL ANIMALS 265
7.3.1.5.2 LARGE ANIMALS 265
7.3.1.6 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 266
7.3.1.6.1 SMALL ANIMALS 266
7.3.1.6.2 LARGE ANIMALS 266
7.3.1.6.3 OTHERS 266
7.3.2 LABORATORY INSTRUMENTS 267
7.3.2.1 HEMATOLOGY ANALYZERS 268
7.3.2.1.1 BY MODE 268
7.3.2.1.1.1 AUTOMATIC 268
7.3.2.1.1.2 SEMI-AUTOMATIC 268
7.3.2.1.2 BY PRICE RANGE 268
7.3.2.1.2.1 HIGH PRICE RANGE 268
7.3.2.1.2.2 STANDARD PRICE RANGE 268
7.3.2.1.3 BY MODALITY, 269
7.3.2.1.3.1 BENCHTOP 269
7.3.2.1.3.2 PORTABLE 269
7.3.2.1.3.3 OTHERS 269
7.3.2.2 CHEMISTRY ANALYZERS 270
7.3.2.2.1 BY MODE 270
7.3.2.2.1.1 AUTOMATIC 270
7.3.2.2.1.2 SEMI-AUTOMATIC 270
7.3.2.2.2 BY MODALITY, 270
7.3.2.2.2.1 BENCHTOP 270
7.3.2.2.2.2 PORTABLE 270
7.3.2.2.3 BY SAMPLE TYPE, 271
7.3.2.2.3.1 BLOOD 271
7.3.2.2.3.2 URINE 271
7.3.2.2.3.3 STOOL 271
7.3.2.2.3.4 OTHERS 271
7.3.2.3 POINT-OF-CARE INSTRUMENTS 272
7.3.2.3.1 BY TYPE 272
7.3.2.3.1.1 LATERAL FLOW POCT 272
7.3.2.3.1.2 MOLECULAR POCT 272
7.3.2.3.1.3 OTHERS 272
7.3.2.3.2 BY MODE 273
7.3.2.3.2.1 AUTOMATIC 273
7.3.2.3.2.2 SEMI-AUTOMATIC 273
7.3.2.4 COAGULATION ANALYZERS 273
7.3.2.4.1 BY CHANNEL, 274
7.3.2.4.1.1.1 4-CHANNEL 274
7.3.2.4.1.1.2 1-CHANNEL 274
7.3.2.4.2 BY SAMPLE TYPE 274
7.3.2.4.2.1 WHOLE BLOOD 274
7.3.2.4.2.2 PLASMA 274
7.3.2.4.3 BY MODALITY, 275
7.3.2.4.3.1 BENCHTOP 275
7.3.2.4.3.2 PORTABLE 275
7.3.2.5 URINALYSIS EQUIPMENT 276
7.3.2.5.1 BY MODE 276
7.3.2.5.1.1 AUTOMATIC 276
7.3.2.5.1.2 SEMI-AUTOMATIC 276
7.3.2.6 REFRACTOMETER 276
7.3.2.6.1 BY MODE, 276
7.3.2.6.1.1 OPTICAL 277
7.3.2.6.1.2 DIGITAL 277
7.3.2.6.2 BY MODALITY, 277
7.3.2.6.2.1 BENCHTOP 277
7.3.2.6.2.2 PORTABLE 277
7.3.2.7 OTHERS 277
7.3.3 REAGENTS & CONSUMABLES 278
7.3.3.1 KITS 279
7.3.3.1.1 PCR KITS 279
7.3.3.1.2 RAPID TEST KITS 279
7.3.3.1.3 MULTIPLEX KITS 279
7.3.3.1.4 ELISA KITS 279
7.3.3.1.5 SAMPLE PREPARATION KITS ISOLATION AND EXTRACTION KITS 279
7.3.3.1.6 OTHERS 279
7.3.3.2 REAGENTS 280
7.3.3.2.1 NUCLEIC ACID EXTRACTION REAGENTS 280
7.3.3.2.2 IMMUNOFLUORESCENCE REAGENTS 280
7.3.3.2.3 COOMBS REAGENTS 280
7.3.3.2.4 OTHERS REAGENTS 280
7.3.4 MEDIA 280
7.3.5 PANEL 280
7.3.6 STRIPS 280
7.3.7 CASSETTE 280
7.3.8 CONTROL STANDARDS 280
7.3.9 PROBES AND PRIMER 280
7.3.10 OTHERS CONSUMABLE AND ACCESSORIES 280
8 NORTH AMERICA VETERINARY MEDICINE MARKET, BY APPLICATION 281
8.1 OVERVIEW 282
8.2 BACTERIAL DISEASES 286
8.2.1 PRODUCTION ANIMALS 286
8.2.2 COMPANION ANIMALS 286
8.3 CANINE ATOPIC DERMATITIS 287
8.3.1 COMPANION ANIMALS 287
8.3.2 PRODUCTION ANIMALS 287
8.4 HEMINTHES INFECTION 288
8.4.1 PRODUCTION ANIMALS 288
8.4.2 COMPANION ANIMALS 288
8.5 ANIMAL CANCER 289
8.5.1 COMPANION ANIMALS 289
8.5.2 PRODUCTION ANIMALS 289
8.6 FOOT AND MOUTH DISEASE 290
8.6.1 PRODUCTION ANIMALS 290
8.6.2 COMPANION ANIMALS 290
8.7 AUTOIMMUNE DISEASES 291
8.7.1 COMPANION ANIMALS 291
8.7.2 PRODUCTION ANIMALS 291
8.8 BLUETONGUE 292
8.8.1 PRODUCTION ANIMALS 292
8.8.2 COMPANION ANIMALS 292
8.9 OTHERS 293
8.9.1 COMPANION ANIMALS 293
8.9.2 PRODUCTION ANIMAL 293
9 NORTH AMERICA VETERINARY MEDICINE MARKET, BY ANIMAL TYPE 294
9.1 OVERVIEW 295
9.2 COMPANION ANIMALS 298
9.2.1 DOGS 299
9.2.2 CATS 299
9.2.3 HORSES 299
9.2.4 OTHERS 299
9.3 PRODUCTION ANIMAL 300
9.3.1 POULTRY 301
9.3.2 CATTLE 301
9.3.3 SWINE 301
9.3.4 FISH 301
9.3.5 SHEEP & GOATS 301
9.3.6 OTHERS 301
10 NORTH AMERICA VETERINARY MEDICINE MARKET, BY DISTRIBUTION CHANNEL 302
10.1 OVERVIEW 303
10.2 RETAIL SALES 306
10.2.1 OFFLINE 307
10.2.1.1 HOSPITAL PHARMACY 307
10.2.1.2 RETAIL PHARMACY 307
10.2.2 ONLINE 308
10.2.2.1 E-COMMERCE PLATFORMS 308
10.2.2.2 COMPANY WEBSITE 308
10.2.2.3 OTHERS 308
10.3 DIRECT TENDER 309
10.4 OTHERS 310
11 NORTH AMERICA VETERINARY MEDICINE MARKET, BY END USER 311
11.1 OVERVIEW 312
11.2 VETERINARY HOSPITALS 316
11.2.1 PRIVATE 316
11.2.2 PUBLIC 316
11.2.3 VETERINARY HOSPITALS BY LEVEL 317
11.2.3.1 TIER 2 317
11.2.3.2 TIER 1 317
11.2.3.3 TIER 3 317
11.3 VETERINARY CLINICS 318
11.3.1 VETERINARY CLINICS BY TYPE 318
11.3.1.1 PUBLIC 318
11.3.1.2 PRIVATE 318
11.4 ANIMAL AND VETERINARY FARMS 319
11.5 REFERENCE LABORATORIES 320
11.6 ACADEMIC AND RESEARCH INSTITUTE 321
11.7 POINT-OF-CARE TESTING/IN-HOUSE TESTING 322
11.8 OTHERS 323
12 NORTH AMERICA VETERINARY MEDICINE MARKET, BY REGION 324
12.1 NORTH AMERICA 326
12.1.1 U.S. 356
12.1.2 CANADA 386
12.1.3 MEXICO 413
13 NORTH AMERICA VETERINARY MEDICINE MARKET: COMPANY LANDSCAPE 440
13.1 COMPANY SHARE ANALYSIS: GLOBAL 440
14 SWOT ANALYSIS 441
15 COMPANY PROFILES 442
15.1 ZOETIS SERVICES LLC SERVICES LLC. 442
15.1.1 COMPANY SNAPSHOT 442
15.1.2 REVENUE ANALYSIS 443
15.1.3 COMPANY SHARE ANALYSIS 443
15.1.4 PRODUCT PORTFOLIO 443
15.1.5 RECENT DEVELOPMENT 444
15.2 MERCK KGAA 446
15.2.1 COMPANY SNAPSHOT 446
15.2.2 REVENUE ANALYSIS 446
15.2.3 COMPANY SHARE ANALYSIS 447
15.2.4 PRODUCT PORTFOLIO 447
15.2.5 RECENT DEVELOPMENT 449
15.3 ELANCO OR ITS AFFILIATES. OR ITS AFFILIATES 450
15.3.1 COMPANY SNAPSHOT 450
15.3.2 REVENUE ANALYSIS 450
15.3.3 COMPANY SHARE ANALYSIS 451
15.3.4 PRODUCT PORTFOLIO 451
15.3.5 RECENT DEVELOPMENT 453
15.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 454
15.4.1 COMPANY SNAPSHOT 454
15.4.2 COMPANY SHARE ANALYSIS 454
15.4.3 PRODUCT PORTFOLIO 455
15.4.4 RECENT DEVELOPMENT 456
15.5 IDEXX LABORATORIES, INC 458
15.5.1 COMPANY SNAPSHOT 458
15.5.2 REVENUE ANALYSIS 458
15.5.3 COMPANY SHARE ANALYSIS 459
15.5.4 PRODUCT PORTFOLIO 459
15.5.5 RECENT DEVELOPMENT 461
15.6 AB SCIENCE 462
15.6.1 COMPANY SNAPSHOT 462
15.6.2 REVENUE ANALYSIS 462
15.6.3 PRODUCT PORTFOLIO 463
15.6.4 RECENT DEVELOPMENT 463
15.7 ADVACARE PHARMA 464
15.7.1 COMPANY SNAPSHOT 464
15.7.2 PRODUCT PORTFOLIO 464
15.7.3 RECENT DEVELOPMENT 465
15.8 ALMAX IMAGING SRL 466
15.8.1 COMPANY SNAPSHOT 466
15.8.2 PRODUCT PORTFOLIO 466
15.8.3 RECENT DEVELOPMENT 466
15.9 ANIVIVE 467
15.9.1 COMPANY SNAPSHOT 467
15.9.2 PRODUCT PORTFOLIO 467
15.9.3 RECENT DEVELOPMENT 470
15.10 BIOMERIEUX 471
15.10.1 COMPANY SNAPSHOT 471
15.10.2 REVENUE ANALYSIS 471
15.10.3 PRODUCT PORTFOLIO 472
15.10.4 RECENT DEVELOPMENT 472
15.11 BIONOTE USA INC. 473
15.11.1 COMPANY SNAPSHOT 473
15.11.2 PRODUCT PORTFOLIO 473
15.11.3 RECENT DEVELOPMENT 476
15.12 BIO-RAD LABORATORIES, INC. 477
15.12.1 COMPANY SNAPSHOT 477
15.12.2 REVENUE ANALYSIS 477
15.12.3 PRODUCT PORTFOLIO 478
15.12.4 RECENT DEVELOPMENT 480
15.13 CANON MEDICAL SYSTEMS EUROPE B.V. 481
15.13.1 COMPANY SNAPSHOT 481
15.13.2 REVENUE ANALYSIS 481
15.13.3 PRODUCT PORTFOLIO 482
15.13.4 RECENT DEVELOPMENT 482
15.14 CARGIL INCORPORATED 483
15.14.1 COMPANY SNAPSHOT 483
15.14.2 PRODUCT PORTFOLIO 483
15.14.3 RECENT DEVELOPMENT 485
15.15 CEVA 486
15.15.1 COMPANY SNAPSHOT 486
15.15.2 PRODUCT PORTFOLIO 486
15.15.3 RECENT DEVELOPMENT 488
15.16 CURELAB ONCOLOGY 489
15.16.1 COMPANY SNAPSHOT 489
15.16.2 PRODUCT PORTFOLIO 489
15.16.3 RECENT DEVELOPMENT 490
15.17 DECHRA PHARMACEUTICALS LIMITED 491
15.17.1 COMPANY SNAPSHOT 491
15.17.2 REVENUE ANALYSIS 491
15.17.3 PRODUCT PORTFOLIO 492
15.17.4 RECENT DEVELOPMENT 494
15.18 DEMEDITEC DIAGNOSTICS GMBH 495
15.18.1 COMPANY SNAPSHOT 495
15.18.2 PRODUCT PORTFOLIO 495
15.18.3 RECENT DEVELOPMENT 497
15.19 DHN 498
15.19.1 COMPANY SNAPSHOT 498
15.19.2 PRODUCT PORTFOLIO 498
15.19.3 RECENT DEVELOPMENT 500
15.20 DIAGNOSTIC IMAGING SYSTEMS 502
15.20.1 COMPANY SNAPSHOT 502
15.20.2 PRODUCT PORTFOLIO 502
15.20.3 RECENT DEVELOPMENT 504
15.21 ESAOTE SPA 505
15.21.1 COMPANY SNAPSHOT 505
15.21.2 PRODUCT PORTFOLIO 505
15.21.3 RECENT DEVELOPMENT 507
15.22 EUROFINS SCIENTIFIC 508
15.22.1 COMPANY SNAPSHOT 508
15.22.2 REVENUE ANALYSIS 509
15.22.3 PRODUCT PORTFOLIO 509
15.22.4 RECENT DEVELOPMENT 510
15.23 EVONIK ANIMAL NUTRITION 511
15.23.1 COMPANY SNAPSHOT 511
15.23.2 REVENUE ANALYSIS 511
15.23.3 1.1.3 PRODUCT PORTFOLIO 512
15.23.4 RECENT DEVELOPMENT 513
15.24 FUJIFILM HOLDINGS CORPORATION 514
15.24.1 COMPANY SNAPSHOT 514
15.24.2 REVENUE ANALYSIS 514
15.24.3 PRODUCT PORTFOLIO 515
15.24.4 RECENT DEVELOPMENT 518
15.25 GOLD STANDARD DIAGNOSTICS 519
15.25.1 COMPANY SNAPSHOT 519
15.25.2 PRODUCT PORTFOLIO 519
15.25.3 RECENT DEVELOPMENT 521
15.26 HALLMARQ VETERINARY IMAGING 522
15.26.1 COMPANY SNAPSHOT 522
15.26.2 PRODUCT PORTFOLIO 522
15.26.3 RECENT DEVELOPMENT 523
15.27 HEBEI VEYONG PHARMACEUTICAL CO., LTD. 524
15.27.1 COMPANY SNAPSHOT 524
15.27.2 PRODUCT PORTFOLIO 524
15.27.3 RECENT DEVELOPMENT 528
15.28 IBIS S.R.L. 529
15.28.1 COMPANY SNAPSHOT 529
15.28.2 PRODUCT PORTFOLIO 529
15.28.3 RECENT DEVELOPMENT 531
15.29 VIRBAC 532
15.29.1 COMPANY SNAPSHOT 532
15.29.2 REVENUE ANALYSIS 533
15.29.3 PRODUCT PORTFOLIO 533
15.29.4 RECENT DEVELOPMENT 536
15.30 VMRD, INC 537
15.30.1 COMPANY SNAPSHOT 537
15.30.2 PRODUCT PORTFOLIO 537
15.30.3 RECENT DEVELOPMENT 539
15.31 HESKA CORPORATION 540
15.31.1 COMPANY SNAPSHOT 540
15.31.2 REVENUE ANALYSIS 540
15.31.3 PRODUCT PORTFOLIO 541
15.31.4 RECENT DEVELOPMENT 542
15.32 KARYOPHARM 543
15.32.1 COMPANY SNAPSHOT 543
15.32.2 REVENUE ANALYSIS 543
15.32.3 PRODUCT PORTFOLIO 544
15.32.4 RECENT DEVELOPMENT 544
15.33 MERIDIAN BIOSCIENCE, INC 545
15.33.1 COMPANY SNAPSHOT 545
15.33.2 PRODUCT PORTFOLIO 545
15.33.3 RECENT DEVELOPMENT 546
15.34 NARANG MEDICAL LIMITED 547
15.34.1 COMPANY SNAPSHOT 547
15.34.2 PRODUCT PORTFOLIO 547
15.34.3 RECENT DEVELOPMENT 551
15.35 NEOGEN CORPORATION 552
15.35.1 COMPANY SNAPSHOT 552
15.35.2 REVENUE ANALYSIS 552
15.35.3 PRODUCT PORTFOLIO 553
15.35.4 RECENT DEVELOPMENT 555
15.36 NIPPON ZENYAKU KOGYO CO., LTD. 556
15.36.1 COMPANY SNAPSHOT 556
15.36.2 PRODUCT PORTFOLIO 556
15.36.3 RECENT DEVELOPMENT 557
15.37 VETDC 558
15.37.1 COMPANY SNAPSHOT 558
15.37.2 PRODUCT PORTFOLIO 558
15.37.3 RECENT DEVELOPMENT 559
15.38 NOVAVIVE INC. 560
15.38.1 COMPANY SNAPSHOT 560
15.38.2 PRODUCT PORTFOLIO 560
15.38.3 RECENT DEVELOPMENT 562
15.39 NUTRECO 563
15.39.1 COMPANY SNAPSHOT 563
15.39.2 PRODUCT PORTFOLIO 563
15.39.3 RECENT DEVELOPMENT 564
15.40 PLANMECA OY 565
15.40.1 COMPANY SNAPSHOT 565
15.40.2 PRODUCT PORTFOLIO 565
15.40.3 RECENT DEVELOPMENT 567
15.41 RANDOX LABORATORIES LTD. 568
15.41.1 COMPANY SNAPSHOT 568
15.41.2 PRODUCT PORTFOLIO 568
15.41.3 RECENT DEVELOPMENT 570
15.42 RINGPU BIOLOGY CO., LTD. 571
15.42.1 COMPANY SNAPSHOT 571
15.42.2 PRODUCT PORTFOLIO 571
15.42.3 RECENT DEVELOPMENT 574
15.43 SHENZHEN SONTU MEDICAL IMAGING EQUIPMENT CO., LTD 575
15.43.1 COMPANY SNAPSHOT 575
15.43.2 PRODUCT PORTFOLIO 575
15.43.3 RECENT DEVELOPMENT 577
15.44 THERMO FISHER SCIENTIFIC INC 578
15.44.1 COMPANY SNAPSHOT 578
15.44.2 REVENUE ANALYSIS 579
15.44.3 PRODUCT PORTFOLIO 579
15.44.4 RECENT DEVELOPMENT 580
15.45 TORIGEN PHARMACEUTICALS INC. 581
15.45.1 COMPANY SNAPSHOT 581
15.45.2 PRODUCT PORTFOLIO 581
15.45.3 RECENT DEVELOPMENT 582
16 QUESTIONNAIRE 583
17 RELATED REPORTS 586
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.